AstraZeneca: ovarian cancer drug Lynparza approved in China

(CercleFinance.com) - AstraZeneca said on Thursday that Lynparza has been approved in China as a first-line maintenance therapy in BRCA-mutated advanced ovarian cancer.


The approval is based on the results from a Phase III trial that showed that Lynparza significantly reduced the risk of disease progression or death by 70% versus placebo.

In 2017, AstraZeneca and US partner Merck announced a global strategic oncology collaboration to jointly develop and market Lynparza.

Copyright (c) 2019 CercleFinance.com. All rights reserved.